Ticker > Company >

Bajaj Healthcare share price

Bajaj Healthcare Ltd.

NSE: BAJAJHCARE BSE: 539872 SECTOR: Pharmaceuticals & Drugs  80.75 K   483   54

476.10
-3.00 (-0.63%)
BSE: Today, 01:16 PM

Price Summary

Today's High

₹ 489

Today's Low

₹ 476.1

52 Week High

₹ 744.9

52 Week Low

₹ 333.2

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1503.68 Cr.

Enterprise Value

1721.85 Cr.

No. of Shares

3.16 Cr.

P/E

31.94

P/B

3.26

Face Value

₹ 5

Div. Yield

0.21 %

Book Value (TTM)

₹  145.89

CASH

4.45 Cr.

DEBT

222.62 Cr.

Promoter Holding

59.19 %

EPS (TTM)

₹  14.91

Sales Growth

14.61%

ROE

11.81 %

ROCE

11.4%

Profit Growth

399.64 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14.61%
3 Year-7.24%
5 Year5.76%

Profit Growth

1 Year147.13%
3 Year-17.91%
5 Year9.37%

ROE%

1 Year11.81%
3 Year8.54%
5 Year17.61%

ROCE %

1 Year11.4%
3 Year9.1%
5 Year16.64%

Debt/Equity

0.4963

Price to Cash Flow

69.55

Interest Cover Ratio

2.6399

CFO/PAT (5 Yr. Avg.)

0.551298020430654

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 59.19 0.00
Mar 2025 59.19 0.00
Dec 2024 59.19 0.00
Sep 2024 59.19 0.00
Jun 2024 67.73 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 109.4451 Cr.
  • Company’s PEG ratio is 0.0882754158012895.
  • The company has a high promoter holding of 59.19%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 12.1496024326931.

 Limitations

  • The company has shown a poor profit growth of -15.5929407231133% for the Past 3 years.
  • The company has shown a poor revenue growth of -7.24270937210496% for the Past 3 years.
  • Tax rate is low at 6.6921.
  • The company is trading at a high PE of 31.94.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 132.25 133.09 122.79 154.47 148.84
Total Expenditure 107.74 108.57 101.15 142.72 124.33
Operating Profit 24.5 24.52 21.64 11.76 24.51
Other Income 0.85 2.61 2.37 13.57 0.88
Interest 8.44 7.88 5.51 6.08 5.23
Depreciation 6.73 6.81 6.85 7.53 5.64
Exceptional Items 0 0 0 0 0
Profit Before Tax 10.18 12.45 11.65 11.72 14.53
Tax 2.16 4.11 -3.31 0.13 2.35
Profit After Tax 8.03 8.34 14.97 11.59 12.18
Adjusted EPS (Rs) 2.91 2.64 4.74 3.67 3.85

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 656.98 679.89 645.8 473.42 542.6
Total Expenditure 520.62 561.23 534.32 397.08 460.03
Operating Profit 136.37 118.66 111.48 76.33 82.58
Other Income 6.91 1.44 1.59 8.69 19.4
Interest 8.34 12.78 17.68 29.75 28.06
Depreciation 16.12 17.64 17.21 27.62 27.92
Exceptional Items 0 0 0 -44.33 0
Profit Before Tax 118.82 89.68 78.18 -16.68 46.01
Tax 35.71 18.3 14.65 -2.35 3.08
Net Profit 83.11 71.39 43.02 -83.79 39.5
Adjusted EPS (Rs.) 30.11 25.87 23.02 -5.19 13.59

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 13.8 13.8 13.8 13.8 15.79
Total Reserves 244.61 314.69 353.89 264.56 450.37
Borrowings 79.71 66.31 93.66 38.58 64.67
Other N/C liabilities 4.93 4.23 2.71 -15.15 -13.66
Current liabilities 182.57 322.07 435.23 402.11 272.27
Total Liabilities 525.63 721.1 899.29 743.27 814.15
Assets
Net Block 208.13 269.74 365.69 252.75 238.45
Capital WIP 57.05 51.98 20.34 4.8 3.45
Intangible WIP 0 0 1.39 1.81 0
Investments 0 0 0 0 0
Loans & Advances 0 0 0 1.14 5.73
Other N/C Assets 2.12 1.07 9.84 78.21 81.12
Current Assets 258.33 398.31 502.04 404.54 485.4
Total Assets 525.63 721.1 899.29 743.27 814.15
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 118.82 89.68 58.22 -103.87 42
Adjustment 24.48 31.47 55.89 169.79 46.42
Changes in Assets & Liabilities -64.09 -110.84 -124.76 39.15 -62.21
Tax Paid -35.65 -9.63 -11.54 -12.79 -4.59
Operating Cash Flow 43.56 0.69 -22.19 92.29 21.62
Investing Cash Flow -108.93 -74.8 -93.43 -11.24 -14.82
Financing Cash Flow 75.46 61.85 131.37 -96.6 -6.38
Net Cash Flow 10.08 -12.27 15.75 -15.55 0.43

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 67.73 59.19 59.19 59.19 59.19
anil champalal jain 5.30 4.63 4.63 4.63 4.63
babita sajankumar bajaj 5.45 4.76 4.76 4.76 4.76
bajaj health & nutritions... 0.87 0.76 0.76 0.76 0.76
bansal pharma limited 0.22 0.19 0.19 0.19 0.19
namrata bajaj 5.91 5.17 5.17 5.17 5.17
nihita sajankumar bajaj 5.87 5.13 5.13 5.13 5.13
padma anil jain 1.10 0.96 0.96 0.96 0.96
sajankumar rameshwarlal b... 35.19 30.75 30.75 37.59 37.59
s k r bajaj huf 7.83 6.84 6.84 - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 32.27 40.81 40.81 40.81 40.81
hdfc mutual fund - hdfc p... - 1.31 1.64 1.64 1.66
llp 0.25 1.14 1.08 1.07 1.12
vanaja sundar iyer - - 2.06 2.22 2.22
weststone management cons... - - 2.06 2.06 2.06
vls finance ltd 2.04 1.32 - - -
maa sharda distributors p... 6.10 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY22
Presentation Q1FY21

Company News

Bajaj Healthcare secures SEC-CDSCO nod for Phase III Clinical Trials of Suvorexant Tablets 4 Oct, 4:30 PM Bajaj Healthcare informs about press release 4 Oct, 2:53 PM Bajaj Healthcare informs about record date 11 Sep, 11:53 AM Bajaj Healthcare informs about record date 9 Sep, 3:07 PM Bajaj Healthcare - Quaterly Results 28 Jul, 6:41 PM Bajaj Healthcare - Quaterly Results 28 Jul, 6:41 PM Bajaj Healthcare - Quaterly Results 28 Jul, 6:41 PM Bajaj Healthcare - Quaterly Results 26 May, 10:03 PM Bajaj Healthcare - Quaterly Results 26 May, 10:03 PM Bajaj Healthcare acquires Genrx Pharmaceuticals 8 Apr, 11:39 AM Bajaj Healthcare informs about press release 19 Mar, 3:09 PM Bajaj Healthcare informs about analyst meet 4 Mar, 2:25 PM Bajaj Healthcare informs about disclosures 25 Feb, 3:05 PM Bajaj Healthcare - Quaterly Results 11 Feb, 6:11 PM Bajaj Healthcare - Quaterly Results 11 Feb, 6:11 PM Bajaj Healthcare informs about disclosure 7 Feb, 12:49 PM Bajaj Healthcare informs about disclosure 30 Jan, 11:45 AM Bajaj Healthcare gets nod for manufacturing of Pimavanserin in India 30 Jan, 10:07 AM Bajaj Healthcare gets exclusive rights to manufacture, market Magnesium L Threonate in India 17 Jan, 10:22 AM Bajaj Healthcare entering into definitive CDMO contract with UK/EU based companies 9 Dec, 6:31 PM Bajaj Healthcare gets TGA’s approval for API Manufacturing Site in Gujarat 7 Dec, 12:05 PM Bajaj Healthcare enters into development and supply agreement with European Entity 23 Sep, 2:11 PM Bajaj Healthcare informs about newspaper publication 27 Aug, 3:57 PM Bajaj Healthcare - Quaterly Results 14 Aug, 6:57 PM Bajaj Healthcare - Quaterly Results 24 May, 9:48 PM Bajaj Healthcare - Quaterly Results 24 May, 9:48 PM Bajaj Healthcare informs about clarification on increase in volume of shares 15 Apr, 5:11 PM Bajaj Healthcare informs about trading window closure 28 Mar, 5:16 PM Bajaj Healthcare informs about business updates 28 Feb, 3:06 PM Bajaj Healthcare enters into definitive CDMO agreement with UK/EU based customers 28 Feb, 1:00 PM Bajaj Healthcare - Quaterly Results 9 Feb, 8:07 PM Bajaj Healthcare - Quaterly Results 9 Feb, 8:07 PM Bajaj Healthcare informs about disclosures 17 Nov, 12:18 PM Bajaj Healthcare informs about earning updates 13 Nov, 4:06 PM Bajaj Healthcare commissions Alkaloid Extraction Plant in Vadodara 19 Oct, 9:18 AM Bajaj Healthcare completes construction of Alkaloid extraction Plant at Vadodara Unit 14 Oct, 11:39 AM Bajaj Healthcare gets EIR from USFDA for API manufacturing facility in Gujarat 14 Sep, 9:37 AM Bajaj Healthcare informs about newspaper advertisement 8 Sep, 4:56 PM Bajaj Healthcare informs about earning updates 16 Aug, 10:09 AM Bajaj Healthcare - Quaterly Results 14 Aug, 12:00 PM Bajaj Healthcare - Quaterly Results 14 Aug, 12:00 PM Bajaj Healthcare - Quaterly Results 30 May, 7:58 PM Bajaj Healthcare - Quaterly Results 30 May, 7:58 PM Bajaj Healthcare - Quaterly Results 13 Feb, 5:48 PM Bajaj Healthcare - Quaterly Results 13 Feb, 5:48 PM Bajaj Healthcare informs about disclosure 14 Dec, 4:52 PM Bajaj Healthcare commences trial runs for Opium Processing Business 23 Nov, 3:47 PM Bajaj Healthcare informs about disclosure 21 Nov, 12:28 PM USFDA completes pre-approval inspection at Bajaj Healthcare’s API facility in Gujarat 18 Nov, 12:25 PM Bajaj Healthcare - Quaterly Results 11 Nov, 12:00 PM

Bajaj Healthcare Stock Price Analysis and Quick Research Report. Is Bajaj Healthcare an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Bajaj Healthcare. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Bajaj Healthcare has a PE ratio of 32.1594858239296 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Bajaj Healthcare has ROA of 5.5128% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Bajaj Healthcare has a Current ratio of 1.7828.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Bajaj Healthcare has a ROE of 11.8106%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Bajaj Healthcare has a Debt to Equity ratio of 0.4963 which means that the company has low proportion of debt in its capital.

  • Sales growth: Bajaj Healthcare has reported revenue growth of 14.6138% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Bajaj Healthcare for the current financial year is 15.2186573446782%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Bajaj Healthcare is Rs 1 and the yield is 0.209%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Bajaj Healthcare is Rs 14.9054. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Bajaj Healthcare in Ticker for free. Also, one can get the intrinsic value of Bajaj Healthcare by using Valuation Calculators, which are available with a Finology ONE subscription. 

Bajaj Healthcare FAQs

Q1. What is Bajaj Healthcare share price today?
Ans: The current share price of Bajaj Healthcare is Rs 479.35.

Q2. What is the market capitalisation of Bajaj Healthcare?
Ans: Bajaj Healthcare has a market capitalisation of Rs 1513.94318462 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Bajaj Healthcare?
Ans: The PE ratio of Bajaj Healthcare is 32.1594858239296 and the P/B ratio of Bajaj Healthcare is 3.2856924493163, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Bajaj Healthcare share?
Ans: The 52-week high share price of Bajaj Healthcare is Rs 745, and the 52-week low share price of Bajaj Healthcare is Rs 333.8.

Q5. Does Bajaj Healthcare pay dividends?
Ans: Currently, Bajaj Healthcare pays dividends. Dividend yield of Bajaj Healthcare is around 0.209%.

Q6. What are the face value and book value of Bajaj Healthcare shares?
Ans: The face value of Bajaj Healthcare shares is Rs 5, while the book value per share of Bajaj Healthcare is around Rs 145.8901. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Bajaj Healthcare?
Ans: Bajaj Healthcare has a total debt of Rs 222.6242 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Bajaj Healthcare?
Ans: The ROE of Bajaj Healthcare is 11.8106% and ROCE of Bajaj Healthcare is 11.4012%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Bajaj Healthcare a good buy for the long term?
Ans: The Bajaj Healthcare long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Bajaj Healthcare undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Bajaj Healthcare appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Bajaj Healthcare’s financials?
Ans: You can review Bajaj Healthcare’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Bajaj Healthcare
X